Answers are grounded in this paper and cite their sources.
Investigates CDNF's impact on social interest in C57Bl/6J mice, indicating potential therapeutic benefits for neurodegenerative conditions.
Cerebral dopamine neurotrophic factor (CDNF) is a promising therapeutic agent in the context of Parkinson’s disease (PD). There is evidence that the neuroprotective properties of CDNF are associated with its regulatory effect on the unfolded protein response (UPR). Behavioral and psychological symptoms are an integral part of PD and other neurodegenerative diseases. However, information on the effect of CDNF on non-motor behavior is very scarce. Therefore, the aim of this study was to investigate the effect of CDNF overexpression in the hippocampus on exploratory, social, anxiety-like, depressive-like behavior and spatial learning, as well as on the expression of UPR genes in C57Bl/6J mice. Four weeks after stereotaxic injection of the adeno-associated viral vector AAV-CDNF, which overexpresses CDNF in the dorsal hippocampus, we found an increase in social interest in the three-chamber social test and the number and duration of social contacts in the resident-intruder test in the CDNF overexpression group. However, CDNF overexpression had no effect on UPR gene expression.
No takes yet. Share an insight, caveat, or question.
D. V. Eremin (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: